FUTURE PLANS

For details of our future plans, see "Business — Our Strategies."

USE OF [REDACTED]

We estimate that we will receive net [**REDACTED**] from the [**REDACTED**] of approximately HK$[**REDACTED**], after deducting [**REDACTED**], fees and other estimated expenses paid and payable by us in connection with the [**REDACTED**], and assuming that the [**REDACTED**] and the [**REDACTED**] are not exercised and an [**REDACTED**] of HK$[**REDACTED**] per H Share, being the mid-point of the indicative [**REDACTED**] of HK$[**REDACTED**] to HK$[**REDACTED**] per H Share.

We currently intend to use the net [**REDACTED**] from the [**REDACTED**] for the following purposes, subject to changes in light of our evolving business needs and changing market conditions:

(a) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for further R&D and planned commercialization of our Core Product, injectable ecnoglutide (XW003), of which:

  (i) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to conduct ongoing and planned clinical trials of injectable ecnoglutide (XW003) in China, including:

    – approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for future investigation and clinical development of adolescent obesity indication. We have initiated a randomized, double-blind, placebo-controlled multi-dose study to evaluate safety, tolerability, PK and PD in Chinese adolescent obese patients (SCW0502-1111). The trial has started its patient enrollment in August 2025 and has enrolled 48 subjects and we expect to complete the Phase Ib study by the first half of 2026. We expect to initiate a Phase III study by the second half of 2026 and plan to enroll approximately 350 to 500 subjects and we expect to complete the Phase III study by the second half of 2028.

    – approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used future investigation and clinical development of moderate-to-severe obesity. We have initiated a multi-center, randomized, open-label, switch therapy study to evaluate efficacy and safety of XW003 versus semaglutide injection (the SLIMMER UP-SWITCH). The trial has started its patient enrollment in July 2025 and plan to enroll approximately 150 to 200 subjects and we expect to complete the trial by early 2027. We expect to initiate an additional Phase II study and Phase III studies by the second half of 2026 and plan to enroll approximately 500 to 600 subjects and we expect to complete the Phase III study by 2029.

    – approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used future investigation and clinical development of MASH. We expect to initiate a Phase IIb study by early 2027 and plan to enroll approximately 100 to 200 subjects and we expect to complete the Phase IIb study by the first half of 2028. We expect to initiate a Phase III study by 2028 and plan to enroll approximately 300 to 400 subjects and we expect to complete the Phase III study by 2030.

– approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for future investigation and clinical development of OSA and other obesity related diseases. We initiated the Phase III study for OSA in February 2026 and plan to enroll approximately 300 to 500 subjects and we expect to complete the Phase III study by 2028. We plan to file IND for other obesity related commorbidities and initiate additional clinical trials in 2026.

See "Business — Our Core Product."

(ii) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for preparation of registration filings and other regulatory matters.

Specifically, this includes costs associated with obtaining relevant product registrations and regulatory approvals in Chinese Mainland, general corporate-level operational expenditures, as well as branding activities to enhance market reputation and raise brand awareness.

(b) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for further R&D of our Key Products, XW004 and XW014, of which:

(i) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to conduct the planned clinical trial for XW004. We have submitted the IND application to the NMPA for XW004 for the treatment of obesity and commenced a Phase Ib/IIa clinical trial in Chinese Mainland in November 2025. We expect to initiate a Phase III clinical study of XW004 for the treatment of overweight/obesity in 2027.

(ii) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used to conduct the ongoing and planned clinical trials for XW014. We completed the Phase I clinical trial of XW014 for the treatment of obesity in the U.S. in the December 2025. We expect to initiate a Phase II clinical trial of XW014 to further explore the efficacy and safety in obese patients as well as the possibility for combination of other treatments in the first half of 2026.

See "Business — Our Key Products."

(c) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for advancing other pipeline assets, including XW015, XW016, XW019, and XW020. We expect to submit IND applications for XW015, XW016 and XW020 in 2026 and the IND application for XW019 in the first half of 2027. We will initiate the Phase I studies for these four assets afterwards;

See "Business — Preclinical-Stage Drug Candidates."

(d) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for enhancing the manufacturing capacity and quality control system to support the commercialization of our Core Product injectable ecnoglutide (XW003).

Specifically, we expect to establish outsourcing collaboration with CMOs, and invest in purchases of manufacturing equipment. We plan to upgrade the production lines by purchasing more manufacturing equipments to enhance our CMO partners' production lines.

(e) approximately [**REDACTED**]%, or HK$[**REDACTED**], will be used for working capital and other general corporate purposes.

The above allocation of the net [**REDACTED**] from the [**REDACTED**] will be adjusted on a pro rata basis in the event that the [**REDACTED**] is fixed at a higher or lower level compared to the mid-point of the indicative [**REDACTED**] stated in this Document.

If the [**REDACTED**] and the [**REDACTED**] are exercised in full, the net [**REDACTED**] that we will receive will be approximately HK$[**REDACTED**], assuming an [**REDACTED**] of HK$[**REDACTED**] per H Share (being the mid-point of the indicative [**REDACTED**]). In the event that the [**REDACTED**] and the [**REDACTED**] are exercised in full, we intent to apply the additional net [**REDACTED**] to the above purposes in the proportions stated above.

To the extent that our net [**REDACTED**] are not sufficient to fund the purposes set out above, we intend to fund the balance through a variety of means, including cash generated from operations, collaboration deals, bank loans and other borrowings.

To the extent that the net [**REDACTED**] from the [**REDACTED**] are not immediately applied to the above purposes and to the extent permitted by relevant law and regulations, we will only deposit such funds in short-term deposits in licensed banks or authorized financial institutions (as defined under the SFO or applicable laws and regulations in other jurisdictions). We will issue an appropriate announcement if there is any material change to the above proposed use of [**REDACTED**].